Plasmalogens vs. NMN and NAD+ for Brain Aging: Membrane Medicine vs. Energy Medicine

Two distinct frameworks have emerged for thinking about brain aging at the molecular level. One focuses on membrane integrity—specifically a class of phospholipids called plasmalogens that are uniquely concentrated in brain tissue and are depleted in Alzheimer’s disease. The other focuses on cellular energy currency: NAD+, and its precursor NMN, which decline with age and impair mitochondrial function, DNA repair, and a class of longevity-linked enzymes called sirtuins. These are sometimes framed as competing explanations, but they may describe different failure modes occurring in parallel.

For people researching shilajit—a resinous mineral exudate used in Ayurvedic medicine—understanding these two frameworks matters because shilajit’s proposed active compounds (fulvic acid, dibenzo-alpha-pyrones, and trace minerals) have mechanisms that overlap more with the energy-medicine side than with the membrane-medicine side. This article explains what each approach entails, what the current evidence actually supports, and where the limits of that evidence lie. Nothing here constitutes medical advice.

What Are Plasmalogens, and Why Does Their Loss Matter?

Plasmalogens are a subclass of phospholipids—molecules that form the bilayer membranes of every cell. What distinguishes them is a vinyl ether bond at the sn-1 position of the glycerol backbone, rather than the ester bond found in conventional phospholipids. This structural difference makes plasmalogen-containing membranes more fluid in certain configurations and more resistant to lipid peroxidation. The brain and heart are the organs with the highest plasmalogen concentration relative to their total phospholipid pool.

In individuals with Alzheimer’s disease, plasmalogen levels in frontal cortex and hippocampal tissue are measurably reduced compared to age-matched controls, and the degree of reduction correlates with cognitive impairment in some observational work. Whether this depletion is a cause of neurodegeneration, a consequence of it, or both is an active research question. Plasmalogens are synthesized in peroxisomes, and peroxisomal dysfunction is itself implicated in aging. Supplemental plasmalogen precursors—typically derived from scallop or chicken byproducts—are being investigated in early clinical trials, primarily in Japan.

None of the peer-reviewed studies cited in this article examined plasmalogens directly. The characterization above reflects the broader scientific literature on brain phospholipid biology. Readers interested in clinical plasmalogen supplementation evidence should seek systematic reviews of those specific trials.

What Is NAD+ and Why Does It Decline with Age?

Nicotinamide adenine dinucleotide (NAD+) is a coenzyme present in every living cell. In its oxidized form, it accepts electrons during glycolysis and the citric acid cycle; in its reduced form (NADH), it donates electrons to the mitochondrial electron transport chain to generate ATP. Beyond energy metabolism, NAD+ is a required substrate for sirtuin enzymes—which regulate gene expression, stress responses, and mitochondrial biogenesis—and for PARP enzymes that repair DNA strand breaks. NAD+ levels in human tissue decline measurably with age, beginning in middle adulthood.

NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside) are NAD+ precursors that, when taken orally, can raise circulating NAD+ levels in humans in short-term trials. Whether raising blood NAD+ meaningfully raises NAD+ in brain tissue—which has its own biosynthetic machinery and is separated from circulation by the blood-brain barrier—is less clearly established. This distinction matters when evaluating whether an NAD+-boosting supplement can plausibly affect neurodegeneration in living people.

Sirtuins: The NAD+-Dependent Enzymes Linked to Brain Protection

Sirtuins (SIRT1–SIRT7) are a family of NAD+-dependent deacylase enzymes. Because they require NAD+ as a co-substrate—not merely a cofactor—their activity is directly coupled to cellular NAD+ availability. When NAD+ is abundant, sirtuins are active; as NAD+ falls with age, sirtuin activity diminishes. SIRT3, located in mitochondria, has received particular attention for its role in regulating antioxidant enzymes and modulating neuroinflammation. In aged mice, SIRT3 activation was associated with suppressed hippocampal neuroinflammation and protection against anesthesia/surgery-induced cognitive decline ^[2].

In the context of acute brain injury, sirtuins have been identified as potential targets for neuroprotection following subarachnoid hemorrhage, with proposed mechanisms involving mitochondrial protection, inflammatory regulation, and apoptosis suppression ^[6]. In an ischemia-reperfusion model, restoration of NAD+ was associated with sirtuin-regulated metabolic homeostasis and reduced brain injury markers ^[4]. These findings come from animal models and acute injury contexts; whether the same mechanisms extend meaningfully to slowly progressive, age-related neurodegeneration in humans requires caution in extrapolation.

The practical point is that if sirtuin activity depends on NAD+ availability, and if NAD+ availability declines with age, then approaches that restore NAD+—whether through precursors like NMN or through compounds that support mitochondrial NAD+/NADH cycling—carry a plausible mechanism-grounded rationale. Plausible mechanism is not clinical proof.

Mitochondrial Energy and the Aging Brain

Neurons are among the most metabolically demanding cells in the body, and much of their energy must be generated locally within axons—often at great distance from the cell body. Research into axonal energy metabolism has highlighted how declining mitochondrial function with age compromises the ATP supply needed to maintain ion gradients, transport cargo along axons, and sustain synaptic transmission ^[5]. This axonal energy crisis is considered a contributor to the dying-back pattern of neurodegeneration seen in several diseases.

Mitochondrial Complex I—the first and largest enzyme in the electron transport chain—accepts electrons from NADH and is the primary entry point for electron flow that drives ATP synthesis. Complex I dysfunction has been identified as a potential therapeutic target in Alzheimer’s disease pathology, with impairment linked to increased oxidative stress and reduced ATP production in vulnerable neurons ^[3]. This directly connects the NAD+/NMN framework to neurodegeneration: if Complex I is functionally impaired or substrate-limited in NADH, ATP generation suffers even when other cellular systems are intact.

Autophagy, Oxidative Stress, and Cellular Housekeeping

Both the membrane-medicine and energy-medicine models of brain aging converge on a shared vulnerability: the accumulation of damaged cellular components. Plasmalogens act as sacrificial antioxidants at the membrane surface, scavenging reactive oxygen species, but cannot clear the products of ongoing damage. NAD+-dependent sirtuins, by contrast, influence autophagy—the process by which cells selectively degrade and recycle damaged organelles and protein aggregates.

Autophagy functions as an essential cellular antioxidant pathway in neurodegenerative disease, acting not primarily by neutralizing free radicals but by removing mitochondria that have become net ROS producers (mitophagy) and clearing aggregate-prone proteins before they reach pathological levels ^[1]. The intersection of NAD+, sirtuin signaling, and autophagy regulation means the energy-medicine approach has at least indirect reach into cellular quality control—a mechanism the membrane-medicine framing addresses less directly.

Where Shilajit Fits in This Picture

Shilajit does not contain plasmalogens and is not a direct plasmalogen precursor. Its proposed mechanisms of action sit primarily on the energy-medicine side. Fulvic acid, the dominant bioactive fraction, is a low-molecular-weight humic substance with documented electron-carrier properties. In cell-based studies, fulvic acid has been shown to associate with mitochondrial membranes and interact with Complex I—the enzyme implicated in Alzheimer’s-related mitochondrial dysfunction ^[3]. Dibenzo-alpha-pyrones (DBPs), which are structurally related to CoQ10, are proposed to support NADH oxidation within the electron transport chain, potentially augmenting endogenous NAD+/NADH cycling.

Trace minerals concentrated in shilajit—including zinc, magnesium, copper, and manganese—serve as essential cofactors for enzymes involved in mitochondrial function and antioxidant defense. Whether these mineral contributions are meaningful at realistic supplemental doses depends on an individual’s baseline mineral status. These are not trivial considerations, but they remain under-studied in controlled human trials.

It is important to state clearly: human clinical evidence for shilajit’s effects on brain aging is thin. Most published research is in vitro or in animal models; human trials examining cognitive endpoints are small, short, and at elevated risk of bias. Shilajit should not be positioned as an equivalent alternative to plasmalogen supplementation or to pharmaceutical-grade NAD+ precursor products—these are meaningfully different interventions at different stages of evidence development.

A Note on the Evidence

The research cited here includes animal models and acute-injury studies; results do not directly predict outcomes in human age-related neurodegeneration, and no supplement discussed—including shilajit—has demonstrated efficacy for preventing or treating dementia in large, well-controlled human trials. Individuals with kidney disease, iron metabolism disorders, hormone-sensitive conditions, or those taking prescription medications should consult a qualified healthcare provider before using shilajit or high-dose NAD+ precursors.

Frequently Asked Questions

What is the core difference between the plasmalogen approach and the NMN/NAD+ approach to brain aging?

Plasmalogens work at the structural level—they are membrane phospholipids that provide fluidity, resist oxidative damage at the cell surface, and support membrane-dependent receptor signaling. NMN and NAD+ work at the metabolic and epigenetic level, fueling mitochondrial ATP production and activating sirtuin enzymes that regulate cellular stress responses and autophagy. Research in animal models links NAD+-dependent sirtuin activity to neuroprotection in both chronic and acute brain injury contexts [PMID 33541361, PMID 37779164], but the two approaches target distinct vulnerabilities.

Can NMN or NAD+ precursors actually reach the brain?

This is a genuine open question. Short-term human trials confirm that oral NMN and NR raise NAD+ in blood and muscle tissue, but the brain has a blood-brain barrier and its own NAD+ biosynthetic pathways. Preclinical data suggest some brain uptake occurs, and NAD+ restoration has been associated with neuroprotective effects and sirtuin-regulated metabolic homeostasis in ischemia models ^[4], but direct human brain NAD+ measurement is technically challenging and rarely included in supplement trials.

Is autophagy relevant to both the membrane and energy approaches?

Autophagy—the cellular process that degrades damaged organelles and protein aggregates—is more directly relevant to the energy-medicine framework. NAD+-dependent sirtuins influence autophagy regulation, and autophagy functions as an essential cellular antioxidant mechanism in neurodegeneration, particularly through the removal of dysfunctional, ROS-producing mitochondria ^[1]. The plasmalogen framework addresses membrane-level oxidative protection but engages autophagy signaling less explicitly.

How does shilajit relate to mitochondrial Complex I specifically?

Fulvic acid in shilajit has been shown in laboratory studies to interact with mitochondrial membranes and Complex I. Separately, research has characterized mitochondrial Complex I dysfunction as a recognized therapeutic target in Alzheimer’s disease, where its impairment contributes to neuronal energy deficit and oxidative stress ^[3]. Shilajit’s dibenzo-alpha-pyrones are structurally analogous to CoQ10 and are proposed to support electron transport. These are mechanistic hypotheses supported primarily by cell and animal data, not established clinical outcomes.

Are plasmalogens better studied than NMN for brain aging in humans?

Neither has strong large-scale human evidence for preventing or reversing dementia. Plasmalogen research has produced small interventional trials—primarily in Japan—showing some signal on cognitive measures; NMN and NR have more human pharmacokinetic data but limited brain-outcome trials. Given that mitochondrial energy failure, membrane dysfunction, and neuroinflammation may all contribute to cognitive decline, these approaches are better understood as addressing complementary mechanisms than as competitors.

Who should be cautious about using shilajit?

People with hemochromatosis or other iron-overload disorders, active kidney disease, or hormone-sensitive conditions should consult a physician before use. Anyone taking anticoagulants, immunosuppressants, or drugs with narrow therapeutic windows should seek professional guidance due to poorly characterized interaction data. Pregnant or breastfeeding individuals should avoid shilajit. Regardless of health status, only use products with documented third-party laboratory testing for heavy metals, as unprocessed shilajit sourced from contaminated regions can carry elevated lead, arsenic, or mercury.

References

1. Giordano S et al. Autophagy as an essential cellular antioxidant pathway in neurodegenerative disease. Redox biology (2014). PMID 24494187
2. Liu Q et al. Sirtuin 3 protects against anesthesia/surgery-induced cognitive decline in aged mice by suppressing hippocampal neuroinflammation. Journal of neuroinflammation (2021). PMID 33541361
3. Trushina E et al. Mitochondrial complex I as a therapeutic target for Alzheimer's disease. Acta pharmaceutica Sinica. B (2022). PMID 35256930
4. Wang XX et al. Neuroprotection of NAD(+) and NBP against ischemia/reperfusion brain injury is associated with restoration of sirtuin-regulated metabolic homeostasis. Frontiers in pharmacology (2023). PMID 37056986
5. Yang S et al. Axonal energy metabolism, and the effects in aging and neurodegenerative diseases. Molecular neurodegeneration (2023). PMID 37475056
6. Lei K et al. Sirtuins as Potential Targets for Neuroprotection: Mechanisms of Early Brain Injury Induced by Subarachnoid Hemorrhage. Translational stroke research (2024). PMID 37779164

As an Amazon Associate we earn from qualifying purchases.